|
Prediction of early prostate cancer recurrence using a liquid biopsy approach. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Janssen; Janssen |
Honoraria - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer/Vital; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck; MSD; Novartis; Pfizer; Roche; Sanofi/Aventis |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; ipsen; Janssen-Cilag; Merck; MSD; Novartis; Roche; Sanofi |
Research Funding - IPSEN (Inst); Janssen-Cilag |
Travel, Accommodations, Expenses - Amgen; Bayer; BMS GmbH & Co. KG; Janssen-Cilag |
|
|
Consulting or Advisory Role - Wren Laboratories |